Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies
FDA Oncology Center's @Falleh_Fallah and colleagues discuss loss of equipoise and other trial conduct challenges in an era of breakthrough therapies - via @JCO_ASCO.
Authors
- Anup Amatya (ORCID: https://orcid.org/0000-0002-8130-5951)
- Jaleh Fallah (ORCID: https://orcid.org/0000-0001-7365-2104)
- Haley Gittleman (ORCID: https://orcid.org/0000-0002-6976-8777)
- Harpreet Singh (ORCID: https://orcid.org/0000-0003-1526-0916)
- Daniel L. Suzman (ORCID: https://orcid.org/0000-0002-1702-6114)
- Richard Pazdur (ORCID: https://orcid.org/0000-0002-4771-9923)
- Flora Mulkey (ORCID: https://orcid.org/0000-0003-0760-2648)
- Paul G. Kluetz (ORCID: https://orcid.org/0000-0002-9796-4791)
- Laleh Amiri‐Kordestani (ORCID: https://orcid.org/0000-0002-0056-5437)
- Paz J. Vellanki (ORCID: https://orcid.org/0000-0003-0782-7935)
- Pallavi S. Mishra‐Kalyani (ORCID: https://orcid.org/0000-0003-2309-0179)
- Sundeep Agrawal (ORCID: https://orcid.org/0000-0002-5447-8590)
- Mallorie H. Fiero (ORCID: https://orcid.org/0000-0001-5536-116X)
- Chi Song (ORCID: https://orcid.org/0000-0003-1108-1750)
- Jeevan Puthiamadathil
Institutions
- United States Food and Drug Administration (US)
- Center for Drug Evaluation and Research (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1200/jco-24-01200
- Citations
- 8
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.28